Provides a platform for the development of Resolvin therapies in inflammatory bowel disease and other inflammation disorders
BRANFORD, CT – (January 22, 2019) – Thetis Pharmaceuticals, a privately-held biopharmaceutical company developing novel small molecule therapies based on a class of potent pro-resolving lipid mediators known as Resolvins, announced today that the U.S. Patent and Trademark Office has granted US Patent No. 10,130,719 providing composition of matter patent protection for its TP-317 drug candidate, a novel derivative of Resolvin E1 (RvE1) targeted at inflammatory bowel disease (IBD), and for novel derivatives of D-Series Resolvins. National filings outside of the United States are underway.
Resolvins, part of the superfamily of Specialized Pro-Resolving Lipid Mediators (SPMs), are endogenous lipid autacoids that play a critical role in regulating inflammation resolution and tissue repair throughout the body. By delivering therapeutic doses of Resolvins to activate these intrinsic pathways, Thetis’ drug candidates offer a new approach to treating inflammatory disease by activating intrinsic inflammation resolution pathways without compromising immune function.
Gary Mathias, co-founder and chief executive officer of Thetis said, “This patent expands the intellectual property foundation of our pipeline of innovative Resolvin-based therapies. Despite demonstrating potent pharmacology across multiple inflammatory diseases, Resolvins and other pro-resolving lipid mediators have been hampered by challenges related to their inherent instability and difficult synthesis. Through our HEALER™ technology and innovative synthetic approach, Thetis has unlocked this potent pharmacology by transforming Resolvins into new chemical entities with improved stability and composition of matter patent protection and developing a scalable synthetic approach”.
About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company developing novel lipid-based small molecule therapies for the treatment of inflammatory diseases. Thetis’ HEALER technology platform enables the pharmaceutical development of Resolvins, a novel class of molecules with the potential to transform the treatment of chronic inflammatory diseases. Its lead candidate, TP-317, is a potential first-in-class, safe, oral therapy targeted at ulcerative colitis and Crohn’s disease. Thetis is targeting initial clinical studies in 2020.
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) and follow Thetis on Twitter (@thetispharma).
Director of Business Development